Role of loss and skew of X chromosome inactivation for developing myelodysplastic syndrome in patients with Klinefelter syndrome: A brief review of the literature Authors: Masahiro Imamura Published: 2023 Klinefelter syndrome (KS) is the most common sex chromosome disorder, occurring in approximately one out of five hundred boys, while only approximately one fourth of adult males with KS are diagnosed [1]. The chromosomal pattern of 47,XXY is seen in 80 % of patients with KS and higher-grade chromosome aneuploidies (48,XXXY, 48,XXYY, or 49,XXXXY), mosaic forms (46,XY/47,XXY, 46,XY/48,XXYY, 45X/46,XY/47,XXY, or 46,XX/47,XXY), or structurally abnormal sex chromosome anomalies are seen in the remaining 20 % [2]. The extra X chromosome due to meiotic chromosomal nondisjunction during gametogenesis is originated from maternal chromosome in 47 % of patients and originated from paternal chromosome in 53 % of patients [3]. Affected patients possess characteristics, such as tall stature, narrow shoulders, broad hips, sparse body hair, gynecomastia, small testes, absent spermatogenesis, normal to moderately reduced Leydig cell function, increased secretion of follicle-stimulating hormone, androgen deficiency, and normal to slightly decreased verbal intelligence. Furthermore, osteoporosis, varicose veins, thromboembolic disease, or diabetes mellitus are observed. Intriguingly, malignancies, such as breast cancers, testicular tumors, leukemias, and lymphomas, sometimes occur in the patients with KS. Breast cancer and mediastinal germ cell tumors are more frequently seen as compared with hematologic malignancies. Male breast cancer has been most highly associated with the 47,XXY mosaicism, showing up to 20–50 times greater incidence in the patients with KS compared to patients with normal karyotype [4]. The mechanism for this phenomenon appears to be due to elevated estrogen-to-testosterone ratio and gonadotropin level, while another possibility is that the presence of two X chromosomes may increase the genetic risk of cancer in men with KS, through loss and skew of X chromosome inactivation (XCI) [5], [6], [7], [8]. Among hematologic malignancies in the patients with KS, an increased risk of non-Hodgkin lymphoma is demonstrated, suggesting that immunologic deficiency is an etiologic factor. Although the patients with KS are at increased risk of acute leukemia (albeit inconsistent) in addition to non-Hodgkin lymphoma, whether they have an increased risk of myelodysplastic syndrome (MDS) is still uncertain. I had examined a 72-year-old male patient with KS who developed MDS with multilineage dysplasia (MDS-MLD). Regarding MDS, four other cases have been reported to date (Table 1). Clonal evolution developed in three cases and the rest case might develop clonal evolution because of the possession of additional chromosomal abnormalities [9], [10], [11], [12].Table 1Myelodysplastic syndromes developed in patients with Klinefelter syndrome.Table 1AgeDisease typeCell sourceChromosomal abnormalityReference70RARS(MDS-RS)AML-MRCBMBMAt the preleukemia49,XXY,+8,+19/50,XY,+8,+8,+19,+21At the leukemic phase49,XY,-X,+8,+8,+19/50,XY,-X,+8,+8,+19,+21Knuutila, 1984[9]68RARS(MDS-RS-MLD)PB with PHABM47,XXY[10]45,XXY,−5,−7,−12,−21,+m1,+m2,del(3p)[3]46,XXY,−5,−7,−12,−21,+m1,+m2,+fra,del(3p)[2]46,XXY,−5,−7,−21,+t(7p;−21q),+m1,t(3;12)(p21;p13)[2]47,XXY[4]Abidi, 1986 [10]73RAEB(MDS-EB)PB with PHA47,XXYGroupFrancois de Cytogenetique Hematologique,1988 [11]59RAEB in T(AML-MRC)PB with PHABM46,XY/47,XXY[20]47,XXY,t(4;7)(q21;q11)[16]/46,XY[4]Yamauchi, 1993 [12]72MDS-MLDPB with PHABM47,XXY[20]47,XXY[20]The present caseAbbreviations used in Table 1.RARS, refractory anemia with ring sideroblasts; MDS-RS, myelodysplastic syndrome with ring sideroblasts; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; RAEB, refractory anemia with excess blasts; MDS-EB, myelodysplastic syndrome with excess blasts; RAEB in T, refractory anemia with excess blasts in transformation; MDS-RS-MLD, myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia, BM, bone marrow; PB, peripheral blood; PHA, phytohemagglutinin; t, translocation; p, short arm of chromosome; q, long arm of chromosome; m, minute chromosome; fra, fragile site; del, deletion. Table 1Myelodysplastic syndromes developed in patients with Klinefelter syndrome.Table 1AgeDisease typeCell sourceChromosomal abnormalityReference70RARS(MDS-RS)AML-MRCBMBMAt the preleukemia49,XXY,+8,+19/50,XY,+8,+8,+19,+21At the leukemic phase49,XY,-X,+8,+8,+19/50,XY,-X,+8,+8,+19,+21Knuutila, 1984[9]68RARS(MDS-RS-MLD)PB with PHABM47,XXY[10]45,XXY,−5,−7,−12,−21,+m1,+m2,del(3p)[3]46,XXY,−5,−7,−12,−21,+m1,+m2,+fra,del(3p)[2]46,XXY,−5,−7,−21,+t(7p;−21q),+m1,t(3;12)(p21;p13)[2]47,XXY[4]Abidi, 1986 [10]73RAEB(MDS-EB)PB with PHA47,XXYGroupFrancois de Cytogenetique Hematologique,1988 [11]59RAEB in T(AML-MRC)PB with PHABM46,XY/47,XXY[20]47,XXY,t(4;7)(q21;q11)[16]/46,XY[4]Yamauchi, 1993 [12]72MDS-MLDPB with PHABM47,XXY[20]47,XXY[20]The present caseAbbreviations used in Table 1.RARS, refractory anemia with ring sideroblasts; MDS-RS, myelodysplastic syndrome with ring sideroblasts; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; RAEB, refractory anemia with excess blasts; MDS-EB, myelodysplastic syndrome with excess blasts; RAEB in T, refractory anemia with excess blasts in transformation; MDS-RS-MLD, myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia, BM, bone marrow; PB, peripheral blood; PHA, phytohemagglutinin; t, translocation; p, short arm of chromosome; q, long arm of chromosome; m, minute chromosome; fra, fragile site; del, deletion. Myelodysplastic syndromes developed in patients with Klinefelter syndrome. Abbreviations used in Table 1. RARS, refractory anemia with ring sideroblasts; MDS-RS, myelodysplastic syndrome with ring sideroblasts; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; RAEB, refractory anemia with excess blasts; MDS-EB, myelodysplastic syndrome with excess blasts; RAEB in T, refractory anemia with excess blasts in transformation; MDS-RS-MLD, myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia, BM, bone marrow; PB, peripheral blood; PHA, phytohemagglutinin; t, translocation; p, short arm of chromosome; q, long arm of chromosome; m, minute chromosome; fra, fragile site; del, deletion. The inactivation of one of the two X chromosomes is essential to equalize the dosage of X-linked genes between females and males (i.e., dosage compensation), because females carry a double dose of X-linked genes and this process is normally random, with an equal probability that either the paternal or maternal X chromosome will be inactivated in each cell [13]. X chromosome-inactive specific transcript (XIST) is expressed exclusively in the inactive X chromosome [14]. The Xist gene in mouse and XIST gene in human encodes a large RNA transcript which lacks protein coding potential and is localized in the nucleus, in direct association with the inactive X chromosome, suggesting that the transcript acts in cis to generate the X inactivation. Kawakami et al. [5] demonstrated that loss of inactive X chromosome followed by gain of active X chromosome led to disruption of the dosage compensation in a prostatic small-cell carcinoma cell line originating from a patient with KS (47,XXY) and a series of female-derived cancer cell lines (breast, ovary, and cervical cancers) (Fig. 1). Indeed, X-linked oncogenes, such as ARAF-1 and ELK-1, are overexpressed in testicular germ cell tumors with multiple active X chromosome, showing the oncogenic implications of X chromosomal gain in these cancers [15]. Loss of XIST in adults can induce the reactivation of some inactive X genes and the presence of supernumerary X chromosomes is often seen in human cancers. Collectively, these data indicate that loss of XCI can result in overexpression of X-linked genes, including oncogenes, which may lead to the induction of oncogenesis.Fig. 1Involvement of loss and skew of XCI in developing hematologic malignancies in patients with KS.Fig 1Abbreviations used in Fig. 1. Xa, active X chromosome; Xi, inactive X chromosome; Xp, paternal X chromosome; Xm, maternal X chromosome; KS, Klinefelter syndrome; ARAF-1, rapidly accelerated fibrosarcoma (RAF) kinase A-1; ELK-1, a member of the ternary complex factor (TCF) subfamily; XCI, X chromosome inactivation; Xist, X chromosome-inactive specific transcript; TET2, ten-eleven translocation 2; DNMT3A, DNA methyltransferase 3A; ASXL1, additional sex comb-like 1. Involvement of loss and skew of XCI in developing hematologic malignancies in patients with KS. Furthermore, disruption of XCI have been implicated in hematologic malignancies (Fig. 1). Yildirim et al. [6] presented evidence that loss of Xist after XCI could cause hematologic malignancies (myeloproliferative neoplasm associated with myelodysplasia) in both Xist∆/∆ and Xist∆/+ mutant female mice. They showed that Xist deletion led to lineage-specific differentiation defects and clonal mouse embryonic fibroblasts [16]. They also found that Xist loss led to preferential upregulation of XCI escape genes compared to XCI subjective genes, showing that the high sensitivity of XCI escape genes to transcriptional upregulation in Xist-deficient cells depends on their low H3K27me3 (Histone H3 that indicates tri-methylation at the fourth lysine residue of the histone H3 protein) occupancy and high chromatin accessibility that modulates preexisting binding of transcriptional factors. However, it still needs to be established whether X-chromosome changes are causative of these diseases in humans. Human hematologic malignancies are supposed to result from overdosage of X chromosome, either from loss of XIST on inactive X chromosome or from duplication of active X chromosome. Hypocellular MDS is more common in women with age-related frequency, and XIST deletion and X chromosome duplications have been observed in these patients. In addition, XIST deletions and X chromosome duplication have been seen in both men and women with several other hematologic malignancies. XCI is a random process and yields an approximate 1:1 distribution of the two cell types [13]. However, skewed XCI, in which one of the cell types is markedly excess (greater than 3:1 which corresponds to the expression of 75 % of one allele), is sometimes seen and may be a primary event due to chance or to genetic factors or secondary due to selection against or in favor of cells with a given phenotype [17]. Such secondary skewing is observed mostly in elderly women or women with X chromosomal rearrangements/mutations in clonal expansion due to growth advantages of one X chromosomal allele [17]. Skewed XCI depends on the age, showing that an incidence of skewing of 8.6 % in normal female neonates,16.4 % in 28–32 years old normal females, and 37.9 % in normal females greater than 60 years [18]. Moreover, skewed XCI levels were clearly elevated in mitotically active blood cells, especially in CD34 positive cells, and in patients with MDS as compared with controls of similar age [8]. XCI is also subjective in patients with KS and skewed XCI occurs ranging from 9.1 to 50.0 % [19]. The frequency of clonal hematopoiesis (CH) of indeterminate potential (CHIP) which is a cellular phenotype describing a premalignant state, in which ≥4 % of blood cell harbors the same somatic mutation, increases with aging. The skewed XCI has been used to determine clonality as a marker of CHIP [7]. Although these are not completely inclusive, the skewed XCI is a sex-specific measurable phenotype and a potential marker of stem cell depletion or polyclonal expansion of hematopoietic stem cells [18]. The CH is a modest genetic predisposition but is influenced by extrinsic factors, such as inflammation, genotoxic stress, or immune attack. The CH results from mutations in a restricted set of genes. Mutations in classical oncogenes and tumor suppressors, such as those involved in cellular growth signaling (JAK2, GNAS, GNB1, CBL) and the DNA damage response (TP53, PPM1D), were observed but were not the most common. Two-thirds of the CH could be accounted for by loss-of-function mutations in two epigenetic regulators (DNMT3A and TET2) involved in DNA methylation. The third most mutated gene was ASXL1, a chromatin regulator, and mutations in splicing factors (SF3B1, SRSF2, PRPF8, U2AF1) were also frequently seen [20]. The most frequently mutated genes, such as DNMT3A, TET2, and ASXL1, have a role in hematopoietic stem cell development and self-renewal. These mutations confer a competitive advantage to the CH (Fig. 1). Aging is associated with a steady increase in the number of somatic mutations in nearly all tissues, including hematopoietic cells, while the relationship between the CH prevalence and age differs depending on each somatic mutation. For instance, the prevalence of DNMT3A-driven CH increases steadily up to the age of seventy, but then more slowly, while TET2-driven CH continues to increase steadily throughout life. The CH driven by splicing factor gene mutations increases rapidly after the age of seventy. Although most of these mutations are of little or nonfunctional consequence, a mutation may give a fitness advantage on a cell followed by the development of hematologic malignancies through clonal expansion. In elderly patients with KS, frequent loss and skew of XCI appears to be prerequisite for the development of hematologic malignancies as well as other cancers and this situation could increase with aging (Fig. 1). Since only 25 % of adults with KS are diagnosed, more extensive survey is required for the patients with MDS and other hematologic malignancies to determine the exact proportion of hematologic malignancies in the patients with KS for predicting and hopefully preventing the development of these diseases. Declaration of Competing Interest The author declares no relevant conflict of interest.